Form 4: Zenas BioPharma CEO Leon O. Moulder Jr. Acquires 25,000 Shares

Zenas BioPharma's CEO, Leon O. Moulder Jr., recently purchased 25,000 shares of common stock at an average price of $6.67 per share.

Summary

• On February 18, 2025, Leon O. Moulder Jr., the CEO and a director of Zenas BioPharma, Inc., acquired 25,000 shares of common stock.
• The shares were purchased at a weighted average price of $6.67, with individual transactions ranging from $6.54 to $6.91.
• Following the transaction, Moulder directly owns 266,155 shares and indirectly owns 1,672,039 shares through Tellus BioVentures LLC.
• Moulder disclaims beneficial ownership of the shares held by Tellus BioVentures LLC except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock purchase by an executive. The purchase itself could be seen as a slightly positive signal, but the disclaimer of beneficial ownership over a large portion of shares tempers this.

Management Comments

• Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity, providing transparency to the market regarding the actions of company executives.

Stakeholder Impact

• The stock purchase by the CEO could be perceived positively by shareholders, signaling confidence in the company's future.

Key Dates

Keywords

Zenas BioPharma, Leon O. Moulder Jr., stock acquisition, Form 4, beneficial ownership, Tellus BioVentures, ZBIO